Paradigm Therapeutics

Welcome to Paradigm Therapeutics! Here at Paradigm, our mission is to improve the lives of patients experiencing serious, life-threatening diseases by the discovery, development and delivery of innovative therapies. Our lead therapy, Zorblisa™, is a proprietary topical therapy being developed for the treatment of patients with Epidermolysis Bullosa (EB).

What is EB?

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder that typically manifests at birth or early childhood. Disease manifestations of EB include fragile skin that leads to blisters, wounds in the epidermis and dermis, poor wound healing, and skin infections that can be life-threatening. The therapeutic needs of these patients are underserved by the current treatment options available which only offer palliative care.

Zorblisa™

Zorblisa™ is a therapy that can be administered across the whole body of EB patients to address the disease manifestations of EB including wound healing, wound burden, and infections.

Paradigm Therapeutics Acquires Late Stage “Breakthrough Therapy” Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)

‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal […]

Improving the Lives of People with Rare Diseases

About Us

What Is EB?

Zorblisa™

Patients & Families